Masimo Debuts 2012 Radical-7® at World Congress of Anaesthesiologists

IRVINE, Calif., March 26, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI), the inventor of rainbow Pulse CO-Oximetry™, rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, debuted its 2012 Radical-7 monitor at the 15th World Congress of Anaesthesiologists conference in Buenos Aires, Argentina, March 25-30, 2012.

(Photo:  http://photos.prnewswire.com/prnh/20120326/LA76174-a)

Once again raising the technologic bar, the 2012 Radical-7 leverages Masimo's breakthrough noninvasive measurements with breakthrough functionality designed to automate the process of care and enable clinicians to instantly adapt to changing monitoring needs in individual patients and care areas. 

The 2012 Radical-7's upgradeable rainbow® SET platform features noninvasive and continuous monitoring of:

• Blood constituents that previously required invasive or complicated procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), pleth variability index (PVI®), carboxyhemoglobin (SpCO®), and methemoglobin (SpMet®)
• Masimo SET measure-through motion and low perfusion pulse oximetry for oxygen saturation (SpO2), pulse rate, and perfusion index
• Respiration rate through a novel acoustic sensor (RRa™) clinically shown to be as accurate if not more than capnography for respiration rate, or even through the plethysmograph waveform (RRp™), though less reliable than RRa.

The 2012 Radical-7 is rainbow® centric, with its intuitive, gesture-control, touch screen that allows SpHb, SpOC, SpCO, SpMet, and RRa to be viewed as prominently as SpO2 and pulse rate.  The 2012 Radical-7 offers exceptionally easy operation and instant adaptability to change displays and settings on the fly.  With a quick touch, drag, and drop, clinicians can move any parameter to and from center and bottom of the display, never losing track of any vital signs.  The instant-trend feature provides the ability to view one or two parameters at once and with a simple finger gesture, clinicians can move, expand, or collapse parameter trends for real-time analysis.  Standard wireless connectivity from integrated 802.11 and Bluetooth® technology in the handheld Radical-7 keeps patients connected even while they are ambulating to enable clinician notification and automate charting and enable meaningful use of electronic health record systems.

(Photo: http://photos.prnewswire.com/prnh/20120326/LA76174-b)

The 2012 Radical-7 includes a variety of features designed to simplify the clinician's life.  Adaptive Threshold Alarm™ helps clinicians manage nuisance alarms and reduces the time required to set patient-specific alarms by automatically adjusting the audible alarm to the patient's baseline.  In Vivo Adjustment™ allows clinicians to adjust the noninvasive measurements to the specific patient and laboratory reference device they use for invasive blood testing. These capabilities received the CE Mark in 2011 and are pending FDA 510(k) clearance. 

The Radical-7 offers unprecedented versatility in multiple care areas with its automatic rotational screen for either horizontal or vertical display and three-in-one capability to be used as: 1) a standalone device for bedside monitoring; 2) a detachable, battery-operated wireless device handheld or wearable device to facilitate untethered monitoring during transport and ambulation; and 3) a multiparameter monitoring interface via SatShare®, allowing hospitals to seamlessly implement rainbow® measurement capabilities in the Radical-7 display while automatically sending the Radical-7's Masimo SET pulse oximetry measurements for display on the multiparameter monitor.  

The 2012 Radical-7 continues to provide respiration rate with unprecedented ease and reliability via revolutionary rainbow Acoustic Monitoring™.  The Radical-7 now also includes the ability to measure respiration rate from the plethysmograph waveform (RRp™), enabling monitoring of breathing status from a standard Masimo SET pulse oximetry or rainbow® Pulse CO-Oximetry sensor in all patients in whom those sensors are indicated. The RRp measurement received the CE Mark in early 2011 and has been available on the Rad-87® monitor, but this is the first time it is available on the Radical-7 in CE Mark countries.  The RRp measurement is determined by the variations in the plethysmograph waveform due to respiration, although the measurement is not possible in all patients or conditions.  For patients in whom reliable and continuous respiration rate monitoring is required, Masimo's acoustic respiration rate (RRa) measurement provides accurate and patient-tolerant monitoring of breathing through an acoustic sensor placed on the neck.  The Radical-7's RRa measurement also provides an important visual indication of breathing through the displayed acoustic waveform.

(Photo: http://photos.prnewswire.com/prnh/20120326/LA76174-c)

The 2012 Radical-7 unleashes the power of rainbow® to help empower clinicians to improve patient outcomes and reduce the cost of care in multiple ways, such as reducing blood transfusion-related costs and detecting bleeding earlier with SpHb, optimizing fluid management with PVI, and enabling reliable detection of respiratory depression with RRa.  

Joe Kiani, Masimo CEO and Chairman of the Board, stated: "We are very proud to introduce the 2012 Radical-7 to the anesthesia community at the World Congress of Anaesthesiologists.  In 2000, we 'wowed' the healthcare industry with the original Radical.  We believe the industry will once again be 'wowed' by the new clinician-centric Radical-7 and what it can do to improve the process of care and ultimately, patient care."

The 2012 Radical-7 can be seen at the World Congress of Anaesthesiologists at Exhibit 64-65.  Masimo also will be hosting a sold-out industry symposium, "Improved Patient Outcomes and Decreased Cost of Care with Masimo rainbow® Technology," on Monday, March 26.  In addition, Masimo will be hosting educational seminars in Exhibit 64-65 throughout the meeting.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care...by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact:

Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: [email protected]

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine  are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

SOURCE Masimo Corporation